Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
05/2005
05/12/2005US20050101629 Compositions of a chromene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
05/12/2005US20050101623 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
05/12/2005US20050101597 Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
05/12/2005US20050101545 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
05/12/2005US20050100989 FSH glycosylation mutant
05/12/2005US20050100986 Compositions and methods for targeting a polypeptide to the central nervous system
05/12/2005US20050100617 Method for improving age-related physiological deficits and increasing longevity
05/12/2005US20050100543 Multivalent carriers of bi-specific antibodies
05/12/2005US20050100535 Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
05/12/2005US20050100519 Glycolic acid, papain, arbutin are hydroxy acids, proteolytic enzymes, skin lightening agents optional to this skin care formulation
05/12/2005CA2585115A1 Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
05/12/2005CA2549971A1 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
05/12/2005CA2544297A1 Use of 2-thia-dibenzo[e, h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
05/12/2005CA2544277A1 Keratin gel and the types 2, 4 and 6 of collagens of frog protein for topical use or for lamina preparation use, such as dressing or powdering in food and complements use and in cosmetic mask manufacturing or in solutions used in cosmetic formulation and medical/pharmaceutical
05/12/2005CA2544190A1 Inhibitors of coronavirus protease and methods of use thereof
05/12/2005CA2544128A1 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
05/12/2005CA2543685A1 Neutrophil activation by immune response modifier compounds
05/12/2005CA2543503A1 Combinations comprising an hsp90 inhibitor and a phophodiesterase inhibitor for treating or preventing neoplasia
05/12/2005CA2543458A1 Process for co-spray drying agents with dry silicified mcc
05/12/2005CA2543296A1 Reconstitutable microsphere compositions useful as ultrasonic contrast agents
05/12/2005CA2543292A1 Reduction of unintended use of transdermal devices
05/12/2005CA2543216A1 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline
05/12/2005CA2543170A1 Compositions and methods for increasing hdl and hdl-2b levels
05/12/2005CA2543089A1 Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications
05/12/2005CA2543087A1 Use of peroxisome proliferator-activated receptor gamma (ppar.gamma.) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions
05/12/2005CA2542875A1 Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells
05/12/2005CA2542277A1 Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
05/12/2005CA2541852A1 Bone morphogenetic protein (bmp) 2a and uses thereof
05/12/2005CA2540869A1 Spill resistant formulations containing clays
05/12/2005CA2537059A1 Anhydrous silver dihydrogen citrate compositions
05/11/2005EP1363899B1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
05/11/2005EP1280531A4 Local anesthetic methods and kits
05/11/2005EP1140124B1 Use of unsaponifiable matters of vegetable oils for preparing a medicine
05/11/2005EP0971898B1 Substituted isoquinolines as ultra short acting neuromuscular blockers
05/11/2005EP0969815B1 Pharmaceutical compositions
05/11/2005CN1615133A Crystalline solids of carvedilol and processes for their preparation
05/11/2005CN1200939C Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/11/2005CN1200930C New crystalline polymorphic form of 1-methyl-5-P-toluoylpyrroel-2-ac-etamidoacetic acid guaiacyl ester (MED 15)
05/11/2005CN1200690C Pressurised metered dose inhalers
05/11/2005CN1200683C Striped dentifrice
05/11/2005CN1200679C Weak ethoxylation dehydrated sorbitol ester composition of washing keratin material
05/10/2005US6890942 Acyl sulfonamides as inhibitors of HIV integrase
05/10/2005US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
05/10/2005US6890549 Reducing levels of bioavailable fat by adminstering alpha-cyclodextrin
05/06/2005WO2005040228A2 Disintegratable films for diagnostic devices
05/06/2005WO2005039507A2 Antimicrobial and antiviral compounds
05/06/2005WO2005039506A2 P70s6 kinase modulators and method of use
05/06/2005WO2005039505A2 Compositions and methods for healthy pregnancy
05/06/2005WO2005039504A2 Compounds and methods for treating toll-like receptor 2-related diseases and conditions
05/06/2005WO2005039502A2 Macromer-melt formulations
05/06/2005WO2005039499A2 Rapidly disintegrating film
05/06/2005WO2005039498A2 Methods of treating cancer with hdac inhibitors
05/06/2005WO2005039497A2 Methods and compositions comprising thalidomide for treatment of fibromyalgia
05/06/2005WO2005039496A2 Inhibitors of cathepsin s
05/06/2005WO2005039495A2 Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
05/06/2005WO2005039494A2 Inhibitors of rnase p proteins as antibacterial compounds
05/06/2005WO2005039492A2 Improved combination bacteriolytic therapy for the treatment of tumors
05/06/2005WO2005039491A2 Certain improved combination bacteriolytic therapy for the treatment of tumors
05/06/2005WO2005039490A2 Methods and compositions for treating cancer
05/06/2005WO2005039489A2 Compositions and methods for the inhibition of bone growth and resorption
05/06/2005WO2005039488A2 Use of cxcr4 protein expression on the surface of stem cells as a marker for tumor tropic potential
05/06/2005WO2005039487A2 Method for early detection of ovarian cancer
05/06/2005WO2005039486A2 Compounds and compositions as protein kinase inhibitors
05/06/2005WO2005039484A2 Indolocarbazole anticancer agents and methods of using same
05/06/2005WO2005039483A2 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
05/06/2005WO2005039482A2 Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof
05/06/2005WO2005039481A2 Oral drug delivery system
05/06/2005WO2005027849A3 Rouge free pharmaceutical water for injection (wfi) water system
05/06/2005WO2005025499A3 Hydrophobic drug compositions containing reconstitution enhancer
05/06/2005WO2005020930A3 Improved syntheses of alitame
05/06/2005WO2005020926A3 Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
05/06/2005WO2005020904A3 Oral neurotherapeutic cefazolin compositions
05/06/2005WO2005018573A3 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
05/06/2005WO2005018566A3 Topical delivery system containing colloidal crystalline arrays
05/06/2005WO2005013902A3 Methods and compositions for inhibiting the proliferation of prostate cancer cells
05/06/2005WO2005011576A3 Digital chromatography
05/06/2005WO2005007113A3 Appetite control compositions and methods of use
05/06/2005WO2005007100A3 Pharmaceutical compositions for topical application
05/06/2005WO2005004818A3 Heterocyclic compounds and their use as anticancer agents
05/06/2005WO2005002502A3 An assay for detecting the presence of processing inhibitory antibodies against the apical membrane antigene-1 of plasmodium falciparum in biological samples
05/06/2005WO2005000226A3 Mixed bed multi-dimensional chromatography systems and methods of making and using them
05/06/2005WO2005000223A3 Method of treating retinopathies and disorders associated with blood vessel loss
05/06/2005WO2004112727A3 Aav virions with decreased immunoreactivity and uses therefor
05/06/2005WO2004112710A3 COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
05/06/2005WO2004110345A8 Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
05/06/2005WO2004103298A3 Apparatus and method for the treatment of infectious disease in keratinized tissue
05/06/2005WO2004093830A3 Model for neurodegenerative disorders
05/06/2005WO2004093785A3 Rhesus monkey bombesin receptor subtype-3 (brs-3), nucleotides encoding same, and uses thereof
05/06/2005WO2004091547A3 Compounds, compositions, and methods
05/06/2005WO2004091539A3 Fluid mixing methods and apparatus
05/06/2005WO2004091537A3 Process for making gel films
05/06/2005WO2004091523A3 Method for identifying ligands specific for structural isoforms of proteins
05/06/2005WO2004091495A3 Compositions and methods related to production of erythropoietin
05/06/2005WO2004091487A3 Hemophilia treatment by inhalation of coagulation factors
05/06/2005WO2004089304A3 Antiandrogens with marginal agonist activity and methods of use
05/06/2005WO2004084807A3 Micro-cluster compositions
05/06/2005WO2004082638A3 Histone deacetylase inhibitors
05/06/2005WO2004080427A3 Method of preventing and treating infections that attack mucosa and assisting rehabilitation thereafter using topically applied ascorbic acid
05/06/2005WO2004080419A3 Humanized antibodies that recognize beta amyloid peptide
05/06/2005WO2004080418A3 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
1 ... 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 ... 295